Sentence examples for psa experience from inspiring English sources

Psoriatic arthritis (PsA) is an inflammatory arthritis that occurs in up to one-third of patients with psoriasis and is usually diagnosed years after the skin disease appears. 1 2 More than 50% of patients with PsA experience progressive, erosive arthritis that is often accompanied by functional impairment.

In conclusion, patients with long-term active PsA experienced clinically important improvement in arthritis, psoriasis and psoriatic nail disorder.

Individuals with both psoriasis and PsA may experience emotional distress and discomfort caused by skin involvement and pain, and physical limitations caused by joint involvement, which could synergistically affect their QOL [ 17, 33, 34].

Over a 6-year period, one-fifth of PsA patients experienced deterioration in physical function.

One hundred and twenty-three (42.3%) RA and PsA patients experienced at least one gastrointestinal symptom during MTX treatment.

Besides well-known gastrointestinal symptoms after MTX, RA and PsA patients experienced these symptoms also before MTX intake.

Approximately two-thirds of PsA patients will experience progressive joint damage, which is often associated with functional loss and disability.

The evaluated markers were chosen based on biomarker publications in PsA and previous experience in TNF-mediated autoimmune diseases including rheumatoid arthritis (RA) and PsA.

Moreover, some PsA patients may experience adverse effects, and not all patients respond adequately requiring sometimes the switch to another biologic agent [ 14].

This study presents the first phase 3 data demonstrating the efficacy of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with PsA and prior experience with traditional DMARDs and/or biologic therapies, including treatment failures.

Before the advent of biologic agents, therapies were employed in PsA based on experience in RA, despite differences in the types of joint damage typical of each disease and despite the lack of evidence to support prevention of clinical or radiographic damage in PsA.